Merck stock reversed higher Thursday, though the company reported another quarter of light sales for its HPV vaccine, Gardasil.

The firm reported revenues of $15.53 billion and adjusted earnings per share of $2.22, surpassing consensus predictions of $15.31 billion and $2.14, respectively.

We recently published a list of 10 Worst Blue Chip Stocks to Buy. In this article, we are going to take a look at where Merck ...

Gardasil sales fell 41% in the first quarter, in line with analysts’ already lowered estimates. Excluding China, revenue from the vaccine increased 14%, the company said. Merck’s shares have ...

Merck on Thursday said its first-quarter adjusted profit rose 7% as lower costs helped offset a 2% decline in sales, reflecting a January decision to pause shipments of its Gardasil vaccine to China ...

Seven weeks after opening a new $1 billion vaccine manufacturing facility in North Carolina, Merck has revealed that it is breaking ground on another $1 billion plant—this one in Wilmington ...

The bottom line: We're maintaining our $111 fair value estimate for wide-moat Merck following a quarter that held both expected Gardasil declines as well as impressive sales of newer products like ...

Today's Research Daily features new research reports on 16 major stocks, including Oracle Corp. (ORCL), IBM Corp. (IBM) and ...

Find insight on Merck, Sanofi and more in the latest Market Talks covering the Health Care sector.

Merck's Q4 results beat expectations, but concerns over Gardasil and Keytruda's patent expirations have weighed on the stock. MRK trades at a depressed valuation with significant EPS growth ...

Gardasil sales fell 41% due to weak China demand. Don’t miss this list of 10 overlooked stocks—including one paying a 9% dividend—before Wall Street catches on. Merck reported quarterly ...

Global pharmaceutical company Merck (NYSE:MRK) reported Q1 CY2025 results exceeding ... Management cited a pronounced decline ...